Abstract
The opioid peptides endomorphins have the potential to act as anti-inflammatory agents for the treatment of chronic inflammatory diseases such as rheumatoid arthritis. Since endomorphins in their native form are susceptible to proteolytic degradation, if they are to be considered as viable therapeutic agents it is necessary to modify their structure in order to confer proteolytic resistance while maintaining bioactivity. Endomorphin analogs have only been previously tested for analgesic activity and some of these compounds have been found to be more potent than the native forms. It is important to test these compounds for anti-inflammatory activity and also to identify intracellular and cytokine release mechanisms underlying their anti-inflammatory activity. Further work towards the identification and characterization of an endomorphin analog(s), optimized for efficacy and biostability, may lead to potential therapeutic application of endomorphins in low doses to patients as an anti-inflammatory drug.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
